The clinically defined PAM50 BC subtype and receptor status were confirmed in most samples according to PAM50 and ESR1 (ER), PGR (PR), and ERBB2 (HER2) gene expression (Supplemental Table 1 and Figure 1D). This evidence concerns the gene ERBB2 and breast cancer.